Loading
Life sciences · Journal article
Bioengineering · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Radiation-induced vaginal injury is an underrecognized complication of cervical cancer radiotherapy and evolves through a pathological continuum involving epithelial depletion, oxidative stress, chronic inflammation, microvascular dysfunction, extracellular-matrix remodeling, fibrosis, loss of tissue compliance, and vaginal stenosis. Current management remains largely supportive and is constrained by short local residence, limited anatomical adaptability, variable adherence, and insufficient control of radiation-specific tissue damage. This Mini-Review examines polymeric biomaterials for the prevention and repair of radiation-induced vaginal injury from a pathobiology–material–function perspective. Three complementary strategies are discussed: local polymeric formulations and mucoadhesive hydrogels for mucosal protection and sustained delivery; personalized dilators, stents, and adaptive devices for maintaining vaginal patency; and regenerative scaffolds and tissue-engineered constructs for restoring epithelial, vascular, stromal, and smooth-muscle compartments. Conventional hyaluronic-acid formulations have progressed furthest clinically, whereas responsive hydrogels, shape-adaptive devices, extracellular-matrix-derived materials, and cell- or exosome-based scaffolds remain predominantly preclinical. Importantly, much of the evidence derives from acute irradiation models, non-irradiated reconstruction studies, or engineering prototypes and therefore does not yet demonstrate durable reversal of chronic fibrosis or stenosis. Future development should prioritize stage-specific multifunctional interventions, fractionated irradiation models, standardized structural and functional outcomes, and rigorous oncological safety assessment. Acellular hydrogels, cell-free hybrid scaffolds, and removable drug-eluting devices may offer the most practical near-term translational routes.